Objectives. Osteocalcin, a small peptide secreted by osteoblasts, has been recently described as a circulating hormone involved in the regulation of energy metabolism. In addition, experimental data suggest a regulation of adipocytes by bone, with a stimulation of adiponectin synthesis by osteocalcin and an inverse relationship between serum adiponectin level and bone mineral density (BMD). However, this relationship has not been explored during chronic kidney disease (CKD). Methods. Osteocalcin, adiponectin and leptin were prospectively measured in a cohort of 61 CKD patients. A new non-invasive 3D bone imaging technique was performed (high-resolution peripheral quantitative computed tomography, HR-pQCT), measuring volumetric BMD (vBMD) and microarchitecture parameters at the distal tibia. Results. Patients' mean age was 67.2 ± 13.9 years and mean GFR 33 ± 12 mL/min/1.73 m 2 . We found a positive association between serum osteocalcin and adiponectin (r = 0.29, P = 0.021). Univariate analysis showed inverse correlations between serum adiponectin and total vBMD (r = −0.33, P = 0.01), cortical thickness (r = −0.34, P = 0.008) and trabecular vBMD (r = −0.27, P = 0.04). These associations remained significant in multivariate analysis between serum adiponectin and total vBMD, cortical vBMD and cortical thickness. Conclusion. We report for the first time an inverse relationship between bone density and adiponectin, as well as a positive association between osteocalcin and adiponectin in CKD II-IV patients.
Introduction
Osteocalcin, a small 46-to 50-amino-acid non-collagenic peptide secreted by osteoblasts and also called bone-Gla protein [1] has recently been described as a circulating hormone involved in the regulation of energy metabolism [2] . At the 'local' bone level, osteocalcin induces bone resorption, by stimulating adhesion and chemotaxis of osteoclasts [1] . At a 'systemic' level, recent experimental data demonstrate that osteocalcin differentially regulates pancreatic β cell proliferation and adipocyte gene expression, increasing insulin secretion and adiponectin synthesis, respectively [3] . Osteocalcin-deficient mice present with a higher bone mass (with an improved functional quality of cortical bone and an increased bone formation) and an increase in visceral fat, altogether with a glucose intolerance [4] . Yamada et al. have shown a negative correlation between glomerular filtration rate (GFR) and plasma osteocalcin levels in predialysis patients [5] .
Adiponectin is a 244-amino-acid protein, secreted by adipocytes and accounting for ∼0.01% of total plasma protein [6] . Adiponectin has a crucial role in energy homeostasis and insulin sensitivity: plasma adiponectin level is decreased in obesity, type 2 diabetes, coronary artery diseases and dyslipidaemia [6] . Adiponectin possesses protective cardiovascular effects and anti-inflammatory properties [6] . Two adiponectin receptor subtypes have recently been described: adipoR1, abundantly expressed in the muscles, and adipoR2, predominantly expressed in the liver [7] . Plasma adiponectin values have been reported to be increased during chronic kidney disease (CKD) [8] . Zoccali et al. demonstrated that plasma adiponectin was an inverse predictor of cardiovascular outcomes among patients with end-stage renal disease (ESRD) [9] . Other studies brought similar conclusions [10, 11] , but some recent publications have challenged this observation [12] [13] [14] .
A number of studies have addressed the relationship between bone and adiponectin. Overall, there seems to be a moderate negative association between adiponectin and bone mineral density (BMD) [15] . Moreover, recent data suggest a regulation of adipocytes by bone, towards an increased production of adiponectin by osteocalcin [2, 16] . We hypothesise that such relations may also occur in CKD patients and might be relevant in the analysis of their excessive cardiovascular risk.
Patients and methods

Patients
We performed bone imaging and biological investigations in a singlecentre prospective cohort of 61 CKD II-IV patients. The study was approved by a local independent ethical committee (Comité de Protection des Personnes Lyon Sud Est II), and all patients gave informed consent after written information had been given.
Biological data
Serum creatinine was measured by a colorimetric method. The simplified MDRD formula was used for the estimation of GFR. 
High-resolution peripheral quantitative computed tomography
Compartmental (total, cortical and trabecular) volumetric BMD (vBMD) and bone microarchitecture (cortical thickness and trabecular parameters, specifically trabecular number, separation and thickness) were measured at the ultradistal tibia using a three-dimensional high-resolution peripheral quantitative computed tomography (HR-pQCT) system (XtremeCT, Scanco Medical AG R , Switzerland). This system uses a two-dimensional detector array in combination with a 0.08-mm point-focus x-ray tube, enabling the simultaneous acquisition of a stack of parallel slices with a nominal resolution (voxel size) of 82 μm [17] . The following settings were used: effective energy of 60 kVp, x-ray tube current of 95 mA and matrix size of 1536 × 1536. At each acquisition, 110 slices were obtained, leading to a three-dimensional representation of ∼9 mm in the axial direction. Exams were performed at the right tibia, except when there was a fracture history at this site.
Statistical analysis
Statistical analysis was performed using the SPSS software R 15.0 for Windows. Univariate comparisons of continuous variables between various groups were performed using a Student t-test or a Wilcoxon signedrank test when variables were not normally distributed. Dichotomous variables were compared using the Pearson χ 2 test. Biological and biological/radiological relationships were studied with Pearson's or Spearman's correlation tests, depending on the distribution of variables. In order to better define the effect of biological and general data on bone density and microarchitecture parameters, two different backward stepwise multivariate analyses were performed: the first analysis evaluated age, GFR, BMI and all significant biomarkers on simple regression (cut-off significance of P < 0.05), and the second analysis focused on clinical data (age, BMI), GFR and adipokines. All statistical tests were performed at the two-sided 0.05 level of significance. Data are presented as mean ± SD. 
Results
The clinical characteristics of patients are summarized in Table 1 . Mean ± SD GFR was 33 ± 12 mL/min per 1.73 m 2 (range 10-70). Among the 61 patients, 18 received native vitamin D, 17 active vitamin D, 14 calcium supplementation, 2 sevelamer, 5 corticosteroids, 3 calcineurin inhibitors (CNI), 8 erythropoietin and 1 bisphosphonate. No patient received lanthanum carbonate or cinacalcet. Three patients had chronic interstitial nephritis, 10 glomerular disease, 17 vascular nephropathy, 3 polycystic kidney disease, 7 type 2 diabetes mellitus, 9 an association of vascular and diabetic nephropathy and 12 another or undetermined nephropathy. Patients receiving corticosteroids had immune chronic diseases or were transplanted (liver or heart) with a CKD secondary to CNI nephrotoxicity.
When analysing hormones, we found a significant increase in osteocalcin serum levels when GFR decreased (r = −0.41, P < 0.001), as illustrated in Figure 1 excluding the three outliers, this association remained significant (r = −0.39, P = 0.003). There was a positive correlation between BMI and leptin (r = 0.54, P < 0.01) and a negative one between BMI and adiponectin (r = −0.41, P < 0.01). There was a positive correlation between serum adiponectin and serum osteocalcin (r = 0.29, P = 0.021), as illustrated in Figure 2 . No relationship was found between the leptin:adiponectin ratio and osteocalcin. When analysing hormones and HR-pQCT parameters, we found that GFR was negatively associated with PTH (r = −0.48, P < 0.01), phosphate (r = −0.50, P < 0.01), osteocalcin (r = −0.41, P < 0.01), 25-OH vitamin D serum levels (r = −0.29, P < 0.05) and cortical vBMD (r = −0.32, P < 0.05). Age was negatively associated with osteocalcin (r = −0.45, P < 0.01), 25-OH vitamin D serum level (r = −0.26, P < 0.05) and cortical vBMD (r = −0.56, P < 0.01). Table 2 summarizes the results of correlation analyses between bone parameters (density and microarchitecture) and biomarkers. Cortical thickness was positively associated with BMI (r = 0.32, P = 0.014) and negatively with adiponectin (r = −0.34, P = 0.008). Trabecular separation was negatively correlated with BMI (r = −0.45, P < 0.001) and serum calcium (r = −0.42, P < 0.05). Figure 3 illustrates the inverse relationships between HRpQCT parameters and serum adiponectin level. There was no correlation between serum leptin and HR-pQCT parameters, nor between the leptin:adiponectin ratio and HR-pQCT parameters.
The backward stepwise multivariate analysis focused on general parameters, and all biomarkers (significance cutoff: 0.05 for univariate analysis) showed that the only negative determinant for total vBMD was serum adiponectin (P = 0.003), and the positive one was vitamin D (P = 0.037). The only positive determinant for cortical vBMD was BMI (P = 0.029), and the negative one was age (P < 0.001). Two negative determinants of cortical thickness were serum adiponectin (P = 0.001) and GFR (P = 0.017). There was no significant determinant for trabecular vBMD, except serum calcium (P = 0.043). The same determinants of trabecular number and separation were found: BMI and serum calcium, in a positive manner for trabecular number (P = 0.003 and 0.007, respectively) and in a negative one for trabecular separation (P = 0.01 and 0.036, respectively). The multivariate analysis focusing on adipokines and general data (GFR, BMI, age) showed that serum adiponectin level was a significant negative predictor of total vBMD (P = 0.002) and cortical vBMD (P = 0.002). Age was also a negative predictor of cortical vBMD (P < 0.001). No variable remained associated with trabecular vBMD and the only significant predictor of trabecular microarchitecture was BMI, with a positive relationship with trabecular number (P = 0.02) and a negative one with trabecular separation (P = 0.03).
Discussion
This study, combining biological markers of bone and phosphate/calcium metabolism and a new non-invasive tridimensional bone imaging technique, allowed us to analyse compartmental vBMD (total, cortical and trabecular) and bone microarchitecture in CKD II-IV patients with emerging mineral and bone disorders associated to CKD (CKD-MBD). In 2000, the US National Institute of Health defined new 'quality' criteria for the diagnosis of osteoporosis in addition to a decreased bone mass. Bone strength is influenced not only by the amount of bone, but also by its spatial distribution, cortical and trabecular microarchitecture, bone turnover and material properties such as matrix mineralization, collagen traits and microdamage. These 'quality' criteria cannot be evaluated with dual X-ray absorptiometry (DXA), and BMD does not reflect histomorphometric changes observed during CKD [18] . In this context, HRpQCT provides an accurate and reproducible evaluation of bone volumetric compartmental densities and microarchitecture but cannot evaluate mineralization defects [17, 18] .
A recent study showed that serum osteocalcin increases when renal function declines [5] . In this study, the accumulation of serum osteocalcin during CKD was confirmed even for a moderate renal dysfunction (mean GFR 33 ± 12, maximal GFR 70 mL/min per 1.73 m 2 ). Data about serum adiponectin and GFR are conflicting in the literature: a second analysis of the Modification of Diet in Renal Disease study (n = 820 patients) showed an inverse relationship between GFR and serum adiponectin [13] whereas other studies did not demonstrate a difference for serum adiponectin concentration between CKD patients and controls [19] . In the present study, we did not find a relationship between serum adiponectin and GFR. Moreover, in previous studies, a relationship (that was not observed in this study) was found between bone and serum leptin: Zoccali et al. demonstrated a negative relationship between serum leptin and both serum PTH and bone ALP levels in 161 haemodialysis patients [20] . Moreover, Coen et al. showed an inverse association between serum leptin and markers of both bone resorption and formation in a study evaluating histomorphometry and adipokines in 46 haemodialysis patients [21] .
We found a positive association between adiponectin and osteocalcin serum levels, similar to that observed in healthy women [15] and in diabetic patients [16] , but this has not been previously described in CKD patients. These clinical results support recent experimental data, demonstrating a regulation of pancreatic β cell proliferation and adipocyte gene expression by osteocalcin, leading to an increased insulin secretion and adiponectin synthesis [3] . However, this study is a cross-sectional study and due to the complexity of bone metabolism in CKD patients, it is difficult to formally conclude a correlation between these variables, since the increased adiponectin serum level could also be interpreted as an epiphenomenon of an increased osteocalcin serum level.
Many studies have shown a link between bone and adiponectin; however, there is no clear understanding of its action on bone. Experimental data are in favour of a positive effect of adiponectin on bone turnover and osteoblastic activation [22] [23] [24] . On the other hand, clinical data favour an inhibitory effect of adiponectin on bone. Richards et al. demonstrated a negative correlation between serum adiponectin level and BMD (assessed by DXA) in a cohort of 1735 non-diabetic women [15] . Jurimae et al. found the same correlation in a cohort of 153 healthy premenopausal women; adiponectin could explain 3-12% of the variation in measured BMD variables [25] . In 2008, Peng et al. found similar results in a cohort of 232 men aged 20-80 years [26] . However, Tamura et al. demonstrated a positive correlation between BMD at the distal radius (DXA) and serum adiponectin level in patients with type 2 diabetes mellitus [27] . Thus, the majority of studies favour a negative effect of adiponectin on BMD.
Using a new bone imaging technique, the present study helps to better define the relationship between adiponectin and bone during CKD. Obesity, frequently associated with a higher BMD, mainly via the generation by the fat cell aromatase of the bone-protective hormone oestradiol [28] , is associated with elevated serum leptin and decreased serum adiponectin. We did not find an association between serum leptin and HR-pQCT parameters, nor between serum leptin:adiponectin ratio and HR-pQCT parameters. Here, through HR-pQCT, we were able to show that adiponectin was not only inversely correlated with total and cortical vBMD and with cortical thickness, but also that this relationship could vary among the different bone compartments. Moreover, our results show a persistent relationship between serum adiponectin and cortical bone even after adjustment for BMI, suggesting a direct role of adiponectin on cortical bone. These observations would not have been possible using a classical DXA evaluation since DXA does not allow the compartmental evaluation of BMD and does not measure bone microarchitecture.
In conclusion, this observation of a possible bone/adipose pathway seems of importance during CKD. Because of the very high morbidity-mortality risk in maintenance dialysis patients, early prevention of pathogenic disorders such as CKD-MBD should be initiated well before ESRD. Adiponectin was showed to have protective cardiovascular effects and anti-inflammatory properties in the general population, which is still under investigation in CKD patients. Figure 4 represents the hypothetical relationships between osteocalcin and adiponectin in CKD patients. Further studies should thus be performed to evaluate a potential 'bone-adipose tissue-vessel' axis in CKD patients, and to thoroughly assess whether the association of severely impaired phosphate/calcium metabolism, damaged bone and vascular calcifications is the consequence of an 'osteocalcin-adiponectin' interaction in CKD patients.
